Valuation: Insmed Incorporated

Market Cap 21.34B 18.55B 17.31B 15.9B 29.97B 2,034B 30.49B 204B 79.96B 1,014B 80.15B 78.38B 3,346B P/E 2026 *
-38x
P/E 2027 * 196x
Enterprise Value 20.78B 18.06B 16.86B 15.48B 29.18B 1,980B 29.69B 199B 77.85B 988B 78.04B 76.31B 3,257B EV / Sales 2026 *
12.2x
EV / Sales 2027 * 7.34x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day-0.15%
1 week-6.00%
Current month-0.15%
1 month-11.78%
3 months-26.12%
6 months-37.36%
Current year-43.43%
1 week 96.42
Extreme 96.42
106.26
1 month 96.42
Extreme 96.42
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%-6.00%-9.42%+344.47% 21.34B
+0.05%+3.08%+38.17%+66.77% 56.7B
+0.28%-6.22%+23.21%+61.75% 51.97B
+1.84%+1.27%-14.06%-13.50% 23.33B
+0.98%-2.44%+31.65%-26.45% 17.44B
+9.91%-2.51%+188.84%+326.19% 14.77B
+3.83%-1.34%+47.77%+165.22% 13.84B
+1.61%+0.56%+439.92%+166.12% 12.12B
+3.14%-12.56%+59.51%+149.39% 11.14B
-0.88%-5.17%+108.37%+141.17% 10.38B
Average +2.06%-2.61%+91.40%+138.11% 23.3B
Weighted average by Cap. +1.36%-2.09%+59.92%+110.79%

Financials

2026 *2027 *
Net sales 1.7B 1.48B 1.38B 1.27B 2.39B 162B 2.43B 16.3B 6.38B 80.98B 6.4B 6.26B 267B 2.78B 2.41B 2.25B 2.07B 3.9B 265B 3.97B 26.55B 10.4B 132B 10.42B 10.19B 435B
Net income -559M -486M -453M -416M -785M -53.26B -798M -5.35B -2.09B -26.56B -2.1B -2.05B -87.6B 70.55M 61.32M 57.25M 52.55M 99.1M 6.72B 101M 675M 264M 3.35B 265M 259M 11.06B
Net Debt -563M -489M -457M -419M -791M -53.67B -805M -5.39B -2.11B -26.76B -2.11B -2.07B -88.28B -979M -850M -794M -729M -1.37B -93.27B -1.4B -9.36B -3.67B -46.51B -3.68B -3.59B -153B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-03 US$98.45 -0.15% 3,546,860
26-07-31 US$98.60 -2.85% 2,902,595
26-07-30 US$101.49 -1.58% 3,363,495
26-07-29 US$103.12 -0.97% 2,195,533
26-07-28 US$104.13 -0.57% 1,945,719
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
98.45USD
Average target price
195.95USD
Spread / Average Target
+99.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock